查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529671

甲癣市场规模、份额、趋势分析报告：按类型、治疗、区域、细分市场预测，2024-2030

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual, White Superficial, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

甲癣市场成长与趋势：

根据Grand View Research, Inc.的最新报告，预计2030年全球甲癣市场规模为49.4亿美元，预计2024年至2030年复合年增长率为4.4%。

甲癣市场的成长归因于甲癣和慢性疾病发病率的增加以及治疗意识的提高。感染疾病会导致心理和社会限制，限制工作和社交生活，因此，为患有感染疾病的患者提供有效且高效的治疗变得重要，进一步推动市场成长。

甲癣的成长是推动整体市场成长的主要因素。这种感染疾病通常称为甲癣或指甲真菌感染疾病，影响着美国14% 以上的人口。然而，儘管甲癣具有高度传染性，并且患甲癣的风险随着老龄化的增长而增加，但大多数人并没有意识到甲癣的危害有多大。

全球灰指甲组织等国际组织与世界各地的公共卫生相关人员和医疗保健专业人员合作，提高对灰指甲的认识并改善世界各地的预防和治疗。预计这将推动对治疗药物的需求。美国疾病管制与预防中心 (CDC) 的 Think Fungus 等政府倡议有助于在患者病程早期识别甲癣等真菌疾病，并确保采取适当的治疗措施。因此，对甲癣治疗的需求正在迅速增加，预计将推动该国市场的成长。

此外，主要参与者正专注于合作研究和合作伙伴关係，以开发新型甲癣治疗方法并保持市场竞争力。例如，2022年8月，Moberg Pharma AB预计将与Padagis Israel Agencies Ltd.签订经销协议，授予Padagis治疗趾甲足癣药物MOB-015在以色列的独家经销权。此外，解决诸如提高患者依从性和减少剂量等问题的技术创新预计将推动市场成长。例如，Intas Pharmaceuticals于2021年10月推出了SB 100mg，这是世界上第一个超级生物利用度的Itraconazole，商品名为Itaspor-SB Forte/Subawin。这项措施预计将显着提高患者的依从性并降低治疗成本。

甲癣市场报告亮点

  • 由于患病率不断增加以及 FDA 为满足不断增长的需求而核准的非专利药数量不断增加，远端甲下甲癣细分市场在 2022 年占据主导地位。
  • 由于易于使用和管理，可提高患者的治疗依从性，预计外用药物领域在预测期内将呈现最快的成长速度。
  • 竞争对手越来越注重购买资本集中专用设备，以维持和发展其竞争优势。
  • 由于医疗保健条件良好、目标人口广泛以及治疗普及率较高，北美在 2022 年占据了最大的市场占有率。

目录

第一章调查方法与范围

第二章甲癣市场：执行摘要

  • 市场概述
  • 类型简介
  • 治疗简介
  • 竞争格局概览

第 3 章：甲癣市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素分析
    • 甲癣发生率增加
    • 提高对甲癣治疗的认识
    • 老年人和糖尿病患者增加
  • 市场限制因素分析
    • 老年人和糖尿病患者增加
  • 指甲癣市场分析工具
    • 产业分析-波特五力分析
    • PESTLE分析
    • 价格分析
    • 管道分析

第四章甲癣市场：按类型估计和趋势分析

  • 全球甲真菌病市场：按类型细分仪表板
  • 全球甲癣市场：类型变异分析
  • 2018-2030年全球甲癣市场规模及趋势分析（按类型）
  • 远端灰指甲
  • 浅层白色灰指甲
  • 近端灰指甲
  • 其他类型

第五章甲癣市场：依治疗方法估算与趋势分析

  • 全球甲癣市场：治疗细分仪表板
  • 全球甲癣市场：治疗差异分析
  • 2018-2030年全球甲癣市场规模与趋势分析（依治疗方法）
  • 口服
  • 外用
  • 其他的

第六章 区域业务分析

  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 公司/竞争对手分类
  • 参与企业概况
  • 财务表现
  • 产品外用
  • 公司市场占有率分析
  • 策略规划，2023 年
    • Bausch Health Companies Inc.
    • GSK plc.
    • Abbott
    • Pfizer, Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Moberg Pharma AB
Product Code: GVR-4-68040-031-4

Onychomycosis Market Growth & Trends:

The global onychomycosis market size was estimated at USD 4.94 Billion in 2030 and is expected to grow at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. Onychomycosis Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type Snapshot
  • 2.3. Treatment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing Incidence of Onychomycosis
    • 3.4.2. Rising Awareness About Treatment of Onychomycosis
    • 3.4.3. Rising Awareness About Treatment of Onychomycosis
    • 3.4.4. Growing Geriatric and Diabetic Populations
  • 3.5. Market Restraint Analysis
    • 3.5.1. Growing Geriatric and Diabetic Populations
  • 3.6. Onychomycosis Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape
    • 3.6.3. Pricing Analysis
    • 3.6.4. Pipeline Analysis

Chapter 4. Onychomycosis Market: Type Estimates & Trend Analysis

  • 4.1. Global Onychomycosis Market: Type Segment Dashboard
  • 4.2. Global Onychomycosis Market: Type Movement Analysis
  • 4.3. Global Onychomycosis Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Estimates & Trend Analysis

  • 5.1. Global Onychomycosis Market: Treatment Segment Dashboard
  • 5.2. Global Onychomycosis Market: Treatment Movement Analysis
  • 5.3. Global Onychomycosis Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Topical
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Global Regional Market Snapshot
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Competitive Scenario
      • 6.4.1.3. Regulatory Framework/Reimbursement Framework
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework/Reimbursement Framework
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Competitive Scenario
      • 6.5.1.3. Regulatory Framework/Reimbursement Framework
      • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework/Reimbursement Framework
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Spain
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework/Reimbursement Framework
      • 6.5.3.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework/Reimbursement Framework
      • 6.5.4.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework/Reimbursement Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework/Reimbursement Framework
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework/Reimbursement Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework/Reimbursement Framework
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Competitive Scenario
      • 6.6.1.3. Regulatory Framework/Reimbursement Framework
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework/Reimbursement Framework
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework/Reimbursement Framework
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework/Reimbursement Framework
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework/Reimbursement Framework
      • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework/Reimbursement Framework
      • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Competitive Scenario
      • 6.7.1.3. Regulatory Framework/Reimbursement Framework
      • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Mexico
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework/Reimbursement Framework
      • 6.7.2.4. Mexico Onychomycosis Market, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework/Reimbursement Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Competitive Scenario
      • 6.8.1.3. Regulatory Framework/Reimbursement Framework
      • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework/Reimbursement Framework
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework/Reimbursement Framework
      • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework/Reimbursement Framework
      • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company /Competition Categorization
  • 7.2. Participant Overview
  • 7.3. Financial Performance
  • 7.4. Product Overview
  • 7.5. Company Market Share Analysis
  • 7.6. Strategy Mapping, 2023
    • 7.6.1. Bausch Health Companies Inc.
      • 7.6.1.1. Overview
      • 7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.1.3. Product Benchmarking
      • 7.6.1.4. Strategic Initiatives
    • 7.6.2. GSK plc.
      • 7.6.2.1. Overview
      • 7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.2.3. Product Benchmarking
      • 7.6.2.4. Strategic Initiatives
    • 7.6.3. Abbott
      • 7.6.3.1. Overview
      • 7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.3.3. Product Benchmarking
      • 7.6.3.4. Strategic Initiatives
    • 7.6.4. Pfizer, Inc.
      • 7.6.4.1. Overview
      • 7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.4.3. Product Benchmarking
      • 7.6.4.4. Strategic Initiatives
    • 7.6.5. Bayer AG
      • 7.6.5.1. Overview
      • 7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.5.3. Product Benchmarking
      • 7.6.5.4. Strategic Initiatives
    • 7.6.6. Teva Pharmaceutical Industries Ltd.
      • 7.6.6.1. Overview
      • 7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.6.3. Product Benchmarking
      • 7.6.6.4. Strategic Initiatives
    • 7.6.7. Cipla Inc.
      • 7.6.7.1. Overview
      • 7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.7.3. Product Benchmarking
      • 7.6.7.4. Strategic Initiatives
    • 7.6.8. Merck & Co., Inc.
      • 7.6.8.1. Overview
      • 7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.8.3. Product Benchmarking
      • 7.6.8.4. Strategic Initiatives
    • 7.6.9. Novartis AG
      • 7.6.9.1. Overview
      • 7.6.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.9.3. Product Benchmarking
      • 7.6.9.4. Strategic Initiatives
    • 7.6.10. Sun Pharmaceutical Industries Ltd.
      • 7.6.10.1. Overview
      • 7.6.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.10.3. Product Benchmarking
      • 7.6.10.4. Strategic Initiatives
    • 7.6.11. Moberg Pharma AB
      • 7.6.11.1. Overview
      • 7.6.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.11.3. Product Benchmarking
      • 7.6.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Incidence of Diseases
  • Table 4 Global Onychomycosis Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 North America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 6 North America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 7 North America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S. Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Europe Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Germany Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 UK Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 France Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 France Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Italy Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 Spain Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Denmark Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Sweden Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Norway Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Onychomycosis Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Japan Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Japan Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 China Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 37 China Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 India Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 39 India Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 South Korea Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 Australia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 45 Thailand Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46 Latin America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Latin America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Brazil Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Mexico Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 52 Mexico Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 Argentina Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Argentina Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 South Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 UAE Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 UAE Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Onychomycosis Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping
  • Fig. 15 Onychomycosis market: Type outlook and key takeaways
  • Fig. 16 Onychomycosis market: Type movement analysis & market share 2023 & 2030
  • Fig. 17 Distal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 White superficial onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Proximal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Onychomycosis market: Treatment outlook and key takeaways
  • Fig. 22 Onychomycosis market: Treatment movement analysis & market share 2023 & 2030
  • Fig. 23 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 Regional Outlook, 2023 & 2030
  • Fig. 28 Regional Market Dashboard
  • Fig. 29 Regional Market: Key Takeaways
  • Fig. 30 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 36 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 45 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 53 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Strategy Mapping